BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Insmed Incorporated (INSM) Reports First Quarter Financial Results


5/7/2013 10:54:37 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MONMOUTH JUNCTION, NJ--(Marketwired - May 07, 2013) - Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, reported financial results for the three months ended March 31, 2013.

Highlights of the first quarter of 2013 and recent weeks included:

  • Phase 3 update. Completed the patient treatment period of the Company's registrational Phase 3 clinical trial of ARIKACE®, the Company's Iiposomal amikacin for inhalation, to treat cystic fibrosis (CF) patients with Pseudomonas lung infections in Europe and Canada and remain on track to report top-line clinical results from the trial in mid-2013.
  • Orphan Drug Designation. Received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of infections caused by non-tuberculous mycobacteria (NTM) for ARIKACE.
  • Cash Payment expected from Premacure. Reported that Premacure AB, recently acquired by Shire plc, elected to obtain all of the Company's rights to receive revenues for former product candidate, IGF-1, under the May 2012 Premacure License Agreement. Insmed expects to receive $11.5 million in May 2013 in exchange for any future royalties from Premacure, and Premacure will assume Insmed's royalty obligations to other parties.
  • Appointed Matt Pauls as Chief Commercial Officer. Mr. Pauls has more than 20 years of experience in the pharmaceutical industry, including senior-level leadership roles in global marketing, sales, reimbursement, new product launches and commercial operations at leading pharmaceutical companies.
  • Appointed Peter Clarke as Vice President of Manufacturing. Mr. Clarke has nearly 30 years of experience in biopharmaceutical manufacturing at both startup and established pharmaceutical companies in Europe and the United States.

"We continue to advance Insmed's transformation into a commercial entity. During the first quarter we made significant progress in executing our hiring plan, advancing our manufacturing strategy and carrying out our clinical trials and regulatory filing preparation for ARIKACE," stated Will Lewis, President and Chief Executive Officer of Insmed.

"We remain on track to report top-line clinical results from our Phase 3 trial in CF mid-year and our Phase 2 trial in NTM before the end of the year. Collectively, these data sets bring us closer to our goal to commercialize a potentially life-saving treatment for patients suffering from these orphan lung diseases."

First Quarter Financial Results

For the first quarter of 2013, Insmed posted a net loss of $13.7 million, or $0.43 per share, compared with a net loss of $6.8 million, or $0.28 per share, for the first quarter of 2012.

Research and development expense in the first quarter increased to $10.3 million from $4.7 million in the first quarter of 2012, primarily due to a $4.6 million increase in external costs for clinical trial activities associated with the Company's Phase 3 CF clinical trial and two-year extension study in Europe and Canada, and its Phase 2 NTM clinical trial in the United States.

General and administrative expense for the first quarter of 2013 increased to $4.0 million from $2.5 million in the first quarter of 2012 primarily due to a $1.0 million increase in professional fees related to the review, accounting and reporting of certain equity awards previously granted to employees and directors that, at the time of the grants, were in excess of annual per-person sub-limits included in the Company's 2000 Stock Incentive Plan. The Company also incurred an additional $0.3 million of non-cash stock compensation expense resulting from re-measuring at fair value these equity awards.

During the first quarter the Company received $1.2 million in cash from the sale of a portion of its New Jersey State net operating losses (NOLs) under the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program). The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits for cash.

Balance Sheet Highlights and Cash Guidance

As of March 31, 2013, Insmed had cash, cash equivalents and a certificate of deposit totaling $81.6 million, compared with $92.9 million as of December 31, 2012. As of March 31, 2013, working capital was $60.6 million, excluding a $2.2 million certificate of deposit that matures in July 2013.

As disclosed in the Company's Form 8-K filed on April 30, 2013, the Company expects to receive $11.5 million in May 2013 from Premacure as a result of Premacure's exercise of an option to obtain a fully paid license to develop, manufacture and commercialize IGF-1, with its natural binding protein, IGFBP-3, for the prevention and treatment of complications of preterm birth.

The Company estimates that its full year 2013 cash requirements to fund operations will be in the range of $45 million to $55 million. The Company expects current cash balances will be sufficient to fund operations into 2014.

Conference Call

Insmed management will host an investment community conference call to discuss these results and answer questions today beginning at 8:30 a.m. Eastern time. Shareholders and other interested parties may participate in the call by dialing 888-803-5993 (domestic) or 706-634-5454 (international) and referencing conference ID number 56371335. The call will also be broadcast live on the Company's website at www.insmed.com.

A replay of the conference call will be accessible two hours after its completion through May 21, 2013, by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 56371335. The call will also be archived for 90 days on the Company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKACE®, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with non-tuberculous mycobacteria (NTM) lung infections. Insmed's Phase 3 registrational study of ARIKACE in CF patients in Europe and Canada has completed and the Company expects top-line clinical results in mid-2013. Insmed's Phase 2 clinical trial in patients with NTM is under way in the United States and Canada, with clinical results expected in late 2013. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements that are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Words, and variations of words, such as "intend," "expect," "will," "anticipate," "believe," "continue," "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of results of preclinical studies and clinical trials and preclinical and clinical data and the anticipated benefits of Insmed's products, and to the Company's cash position and financing needs, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company's product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company's product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, inability to successfully develop the Company's product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company's financing requirements or ability raise additional capital, and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. The Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances or changes in its expectations.

-Tables to Follow-

                                                                            
                            INSMED INCORPORATED                             
                        Consolidated Balance Sheets                         
         (in thousands, except par value, share and per share data)         
                                                                            
                                                                            
                                                   March 31,   December 31, 
                                                     2013          2012     
                                                 ------------  ------------ 
                                                  (unaudited)               
Assets                                                                      
Current assets:                                                             
  Cash and cash equivalents                      $     79,434  $     90,782 
  Certificate of deposit                                2,173         2,153 
  Prepaid expenses and other current assets             1,418           643 
                                                 ------------  ------------ 
    Total current assets                               83,025        93,578 
                                                                            
In-process research and development                    58,200        58,200 
Other assets                                              110           117 
Fixed assets, net                                       1,681         1,666 
                                                 ------------  ------------ 
    Total assets                                 $    143,016  $    153,561 
                                                 ============  ============ 
                                                                            
Liabilities and shareholders' equity                                        
Current liabilities:                                                        
  Accounts payable                               $      8,184  $      7,060 
  Accrued expenses                                      5,329         2,933 
  Accrued compensation                                  1,359         2,207 
  Accrued lease expense, current                          298           295 
  Deferred rent                                           144           149 
  Capital lease obligations, current                       83            96 
  Current portion of long term debt                     4,875         3,007 
                                                 ------------  ------------ 
    Total current liabilities                          20,272        15,747 
                                                                            
Accrued lease expense, long-term                          580           647 
Capital lease obligations, long-term                       48            64 
Debt, long-term                                        14,511        16,221 
                                                 ------------  ------------ 
    Total liabilities                                  35,411        32,679 
                                                 ------------  ------------ 
                                                                            
                                                                            
Shareholders' equity:                                                       
Common stock, $0.01 par value; 500,000,000                                  
 authorized shares, 31,571,926 and 31,488,204                               
 issued and outstanding shares at March 31, 2013                            
 and December 31, 2012, respectively                      316           315 
  Additional paid-in capital                          455,725       455,325 
Warrant to purchase 329,932 shares of common                                
 stock for $2.94 per share at March 31, 2013 and                            
 December 31, 2012                                        790           790 
  Accumulated deficit                                (349,226)     (335,548)
                                                 ------------  ------------ 
Total shareholders' equity                            107,605       120,882 
                                                 ------------  ------------ 
    Total liabilities and shareholders' equity   $    143,016  $    153,561 
                                                 ============  ============ 
                                                                            
                                                                            
                            INSMED INCORPORATED                             
               Consolidated Statements of Comprehensive Loss                
                   (in thousands, except per share data)                    
                                                                            
                                                                            
                                                       Three Months Ended   
                                                            March 31,       
                                                        2013        2012    
                                                     ----------  ---------- 
                                                                            
Revenues                                             $        -  $        - 
                                                     ----------  ---------- 
                                                                            
Operating expenses:                                                         
  Research and development                               10,334       4,739 
  General and administrative                              3,975       2,525 
                                                     ----------  ---------- 
    Total operating expenses                             14,309       7,264 
                                                     ----------  ---------- 
                                                                            
Operating loss                                          (14,309)     (7,264)
                                                                            
Investment income                                            51         418 
Interest expense                                           (643)         (2)
Gain on sale of assets, net                                   2           5 
                                                     ----------  ---------- 
    Loss before income taxes                            (14,899)     (6,843)
                                                                            
Provision (benefit) for income taxes                     (1,221)          2 
                                                     ----------  ---------- 
                                                                            
Net loss                                             $  (13,678) $   (6,845)
                                                     ==========  ========== 
                                                                            
Basic and diluted net loss per share                 $    (0.43) $    (0.28)
                                                     ==========  ========== 
                                                                            
Weighted average basic and diluted common shares                            
 outstanding                                             31,554      24,860 
                                                     ==========  ========== 
                                                                            
                                                                            
Net loss                                             $  (13,678) $   (6,845)
Comprehensive loss:                                                         
  Unrealized gains on investments, net of taxes               -         216 
                                                     ----------  ---------- 
Comprehensive loss                                   $  (13,678) $   (6,629)
                                                     ==========  ========== 
                                                                            

Investor Relations Contacts:
LHA

Anne Marie Fields
Senior Vice President
212-838-3777
afields@lhai.com

Bruce Voss
Managing Director
310-691-7100
bvoss@lhai.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES